The Experts below are selected from a list of 2150121 Experts worldwide ranked by ideXlab platform
Johan Undén - One of the best experts on this subject based on the ideXlab platform.
-
Clinical Use of the Calcium-Binding S100B Protein, a Biomarker for Head Injury.
Methods in molecular biology (Clifton N.J.), 2019Co-Authors: Ramona Astrand, Johan UndénAbstract:S100B is a calcium-binding Protein most abundant in neuronal tissue. It is expressed in glial cells and Schwann cells and exerts both intra- and extracellular effects. Depending on the concentration, secreted S100B exerts either trophic or toxic effects. Its functions have been extensively studied but are still not fully understood. It can be measured in cerebrospinal fluid and in blood, and increased S100B level in blood can be seen after, e.g., traumatic brain injury, certain neurodegenerative disorders, and malignant melanoma. This chapter provides a short background of Protein S100B, commercially available methods of analysis, and its clinical use, especially as a biomarker in minor head injury.
-
Clinical Use of the Calcium-Binding S100B Protein
Methods in molecular biology (Clifton N.J.), 2012Co-Authors: Ramona Astrand, Johan Undén, Bertil RomnerAbstract:Abstract S100B is a calcium-binding Protein most abundant in neuronal tissue. It is expressed in glia cells and Schwann cells and exerts both intra- and extracellular effects. Depending on the concentration, secreted S100B exerts either trophic or toxic effects. Its functions have been extensively studied but are still not fully understood. It can be measured in cerebrospinal fluid and blood, and increased S100B level in blood can be seen after, e.g., traumatic brain injury, certain neurodegenerative disorders and malignant melanoma. This chapter provides a short background of Protein S100B, commercially available methods of analysis, and its clinical use.
-
comparison between capillary venous and arterial levels of Protein S100B in patients with severe brain pathology
Clinical Chemistry and Laboratory Medicine, 2012Co-Authors: Ramona Astrand, Bertil Romner, Peter Reinstrup, Lennart Friishansen, Johan UndénAbstract:Background: Protein S100B is soon in clinical use as a sensitive marker after mild traumatic head injury in adults. Initial studies of S100B in pediatric head injury have shown promising results. Venous sampling can be challenging in children and capillary samples are often a preferred option. The aim of the study was to investigate the relation between capillary, venous and arterial measurements of Protein S100B, primarily by determining whether capillary S100B differ from venous and if capillary S100B can predict venous S100B levels, and secondarily, if arterial S100B samples can substitute venous samples in severely brain-injured patients. Methods: Venous, arterial and capillary blood samples for S100B were collected simultaneously once a day for a maximum of 6 days. Patients were >= 18 years old and admitted to neurointensive care due to severe brain pathology. Results: Capillary S100B samples were on average 0.08 mu g/L higher than venous S100B samples. Prediction of venous concentration from capillary samples yielded a prediction error of 0.07 mu g/L. The mean difference between venous and arterial samples was 0.01 mu g/L. The mean prediction error was 0.03 mu g/L. Conclusions: Capillary and venous serum S100B are not interchangeable, and should be considered as two separate, although related, variables. Arterial measurements of S100B can successfully predict the corresponding venous concentration. (Less)
-
Chapter 11:Protein S100B in Traumatic Brain Injury
Biomarkers for Traumatic Brain Injury, 2012Co-Authors: Ramona Astrand, Johan Undén, Bertil RomnerAbstract:Protein S100B is a small calcium-binding Protein expressed in astroglial cells in the central nervous system. Its concentration increases in cerebrospinal fluid and blood after traumatic brain injury. There are several commercially available methods for analyzing serum S100B. The clinical use of serum S100B is mainly in minor head injury, as a complement to existing guidelines in order to help clinicians to determine who could safely be discharged without a previous CT scan. S100B in severe TBI is still being studied as a marker for secondary neurological complications, but has not yet had an impact in this specific area. Recent research on the clinical use of S100B in pediatric TBI has shown promising results, and the introduction of S100B in minor head injuries could have even greater impact than for adults. However, more research needs to be done before a biomarker can be clinically used in pediatric TBI.
-
Reference values for venous and capillary S100B in children.
Clinica chimica acta; international journal of clinical chemistry, 2011Co-Authors: Ramona Astrand, Bertil Romner, Jan Lanke, Johan UndénAbstract:The current management guidelines for pediatric mild head injury (MHI) liberally recommend computed tomography (CT) and frequent admission. Serum Protein S100B, currently used in management of adult head injury, has recently shown potential for reducing unnecessary CT scans after pediatric mild head injury. Capillary sampling in children is commonly used when venous sampling fails or is inappropriate. We present reference values for both venous and capillary samples of Protein S100B in children. Neurologically healthy children aged 1-16, scheduled for minor surgery requiring general anesthesia, were prospectively included. Samples for S100B were drawn before (venous) and after (venous and capillary) sedation. Serum values of 455 children (255 boys, 200 girls) aged 1-14 were computed. S100B was higher in younger children for both venous (r=-0.32) and capillary samples (r=-0.28). Reference levels for children aged 1 and 2 were significantly higher than for children aged 3-14 years (venous 0.15 μg/L, capillary 0.37 μg/L). For capillary blood, a gender difference was found in the youngest age groups. We present reference values for venous and capillary S100B in healthy children. These results can be utilized when considering future studies on pediatric head injury and S100B levels. Copyright © 2011 Elsevier B.V. All rights reserved.
Andrea Kleindienst - One of the best experts on this subject based on the ideXlab platform.
-
treatment with the neurotrophic Protein S100B increases synaptogenesis after traumatic brain injury
Journal of Neurotrauma, 2020Co-Authors: Justus Baecker, Krista Mineia Wartchow, Tina Sehm, Ali Ghoochani, Michael Buchfelder, Andrea KleindienstAbstract:Release of neurotrophic and growth factors such as S100 calcium-binding Protein B (S100B) yields an endogenous repair mechanism following traumatic brain injury (TBI). Although nanomolar S100B conc...
-
Intraperitoneal treatment with S100B enhances hippocampal neurogenesis in juvenile mice and after experimental brain injury
Acta neurochirurgica, 2013Co-Authors: Andrea Kleindienst, Felicitas Grünbeck, Rolf Buslei, Irene Emtmann, Michael BuchfelderAbstract:Background Neurogenesis is documented in adult mammals including humans, is promoted by neurotrophic factors, and constitutes an innate repair mechanism following brain injury. The glial neurotrophic Protein S100B is released following various types of brain injuries, enhances hippocampal neurogenesis and improves cognitive function following brain injury in rats when applied intrathecally. The present study was designed to elucidate whether the beneficial effect of S100B on injury-induced neurogenesis can be confirmed in mice when applied intraperitoneally (i.p.), and whether this effect is dose-dependent.
-
The neurotrophic Protein S100B: value as a marker of brain damage and possible therapeutic implications.
Progress in brain research, 2007Co-Authors: Andrea Kleindienst, M. Ross Bullock, Felicitas Hesse, Michael BuchfelderAbstract:We provide a critical analysis of the value of S100B as a marker of brain damage and possible therapeutic implications. The early assessment of the injury severity and the consequent prognosis are of major concern for physicians treating patients suffering from traumatic brain injury (TBI). A reliable indicator to accurately determine the extent of the brain damage has to meet certain requirements: (i) to originate in the central nervous system (CNS) with no contribution from extracerebral sources; (ii) a passive release from damaged neurons and/or glial cells without any stimulated active release; (iii) a lack of specific effects on neurons and/or glial cells interfering with the initial injury; (iv) an unlimited passage through the blood-brain barrier (BBB). The measurement of putative biochemical markers, such as the S100B Protein, has been proposed in this role. Over the past decade, numerous studies have reported a positive correlation of S100B serum levels with a poor outcome following TBI. However, some studies raise doubt whether the serum measurement of S100B is a valid biochemical marker of brain damage. We summarize the specific properties of S100B and analyze whether they support or counteract the necessary requirements to designate this Protein as an indicator of brain damage. Finally, we report recent experimental findings suggesting a possible therapeutic potential of S100B.
-
A Critical Analysis of the Role of the Neurotrophic Protein S100B in Acute Brain Injury
Journal of neurotrauma, 2006Co-Authors: Andrea Kleindienst, M. Ross BullockAbstract:We provide a critical analysis of the relevance of S100B in acute brain injury emphazising the beneficial effect of its biological properties. S100B is a calcium-binding Protein, primarily produced by glial cells, and exerts auto- and paracrine functions. Numerous reports indicate, that S100B is released after brain insults and serum levels are positively correlated with the degree of injury and negatively correlated with outcome. However, new data suggest that the currently held view, that serum measurement of S100B is a valid "biomarker" of brain damage in traumatic brain injury (TBI), does not acknowlege the multifaceted release pattern and effect of the blood-brain barrier disruption upon S100B levels in serum. In fact, serum and brain S100B levels are poorly correlated, with serum levels dependent primarily on the integrity of the blood-brain barrier, and not the level of S100B in the brain. The time profile of S100B release following experimental TBI, both in vitro and in vivo, suggests a role of S100B in delayed reparative processes. Further, recent findings provide evidence, that S100B may decrease neuronal injury and/or contribute to repair following TBI. Hence, S100B, far from being a negative determinant of outcome, as suggested previously in the human TBI and ischemia literature, is of potential therapeutic value that could improve outcome in patients who sustain various forms of acute brain damage.
Ramona Astrand - One of the best experts on this subject based on the ideXlab platform.
-
Clinical Use of the Calcium-Binding S100B Protein, a Biomarker for Head Injury.
Methods in molecular biology (Clifton N.J.), 2019Co-Authors: Ramona Astrand, Johan UndénAbstract:S100B is a calcium-binding Protein most abundant in neuronal tissue. It is expressed in glial cells and Schwann cells and exerts both intra- and extracellular effects. Depending on the concentration, secreted S100B exerts either trophic or toxic effects. Its functions have been extensively studied but are still not fully understood. It can be measured in cerebrospinal fluid and in blood, and increased S100B level in blood can be seen after, e.g., traumatic brain injury, certain neurodegenerative disorders, and malignant melanoma. This chapter provides a short background of Protein S100B, commercially available methods of analysis, and its clinical use, especially as a biomarker in minor head injury.
-
Clinical Use of the Calcium-Binding S100B Protein
Methods in molecular biology (Clifton N.J.), 2012Co-Authors: Ramona Astrand, Johan Undén, Bertil RomnerAbstract:Abstract S100B is a calcium-binding Protein most abundant in neuronal tissue. It is expressed in glia cells and Schwann cells and exerts both intra- and extracellular effects. Depending on the concentration, secreted S100B exerts either trophic or toxic effects. Its functions have been extensively studied but are still not fully understood. It can be measured in cerebrospinal fluid and blood, and increased S100B level in blood can be seen after, e.g., traumatic brain injury, certain neurodegenerative disorders and malignant melanoma. This chapter provides a short background of Protein S100B, commercially available methods of analysis, and its clinical use.
-
comparison between capillary venous and arterial levels of Protein S100B in patients with severe brain pathology
Clinical Chemistry and Laboratory Medicine, 2012Co-Authors: Ramona Astrand, Bertil Romner, Peter Reinstrup, Lennart Friishansen, Johan UndénAbstract:Background: Protein S100B is soon in clinical use as a sensitive marker after mild traumatic head injury in adults. Initial studies of S100B in pediatric head injury have shown promising results. Venous sampling can be challenging in children and capillary samples are often a preferred option. The aim of the study was to investigate the relation between capillary, venous and arterial measurements of Protein S100B, primarily by determining whether capillary S100B differ from venous and if capillary S100B can predict venous S100B levels, and secondarily, if arterial S100B samples can substitute venous samples in severely brain-injured patients. Methods: Venous, arterial and capillary blood samples for S100B were collected simultaneously once a day for a maximum of 6 days. Patients were >= 18 years old and admitted to neurointensive care due to severe brain pathology. Results: Capillary S100B samples were on average 0.08 mu g/L higher than venous S100B samples. Prediction of venous concentration from capillary samples yielded a prediction error of 0.07 mu g/L. The mean difference between venous and arterial samples was 0.01 mu g/L. The mean prediction error was 0.03 mu g/L. Conclusions: Capillary and venous serum S100B are not interchangeable, and should be considered as two separate, although related, variables. Arterial measurements of S100B can successfully predict the corresponding venous concentration. (Less)
-
Chapter 11:Protein S100B in Traumatic Brain Injury
Biomarkers for Traumatic Brain Injury, 2012Co-Authors: Ramona Astrand, Johan Undén, Bertil RomnerAbstract:Protein S100B is a small calcium-binding Protein expressed in astroglial cells in the central nervous system. Its concentration increases in cerebrospinal fluid and blood after traumatic brain injury. There are several commercially available methods for analyzing serum S100B. The clinical use of serum S100B is mainly in minor head injury, as a complement to existing guidelines in order to help clinicians to determine who could safely be discharged without a previous CT scan. S100B in severe TBI is still being studied as a marker for secondary neurological complications, but has not yet had an impact in this specific area. Recent research on the clinical use of S100B in pediatric TBI has shown promising results, and the introduction of S100B in minor head injuries could have even greater impact than for adults. However, more research needs to be done before a biomarker can be clinically used in pediatric TBI.
-
Reference values for venous and capillary S100B in children.
Clinica chimica acta; international journal of clinical chemistry, 2011Co-Authors: Ramona Astrand, Bertil Romner, Jan Lanke, Johan UndénAbstract:The current management guidelines for pediatric mild head injury (MHI) liberally recommend computed tomography (CT) and frequent admission. Serum Protein S100B, currently used in management of adult head injury, has recently shown potential for reducing unnecessary CT scans after pediatric mild head injury. Capillary sampling in children is commonly used when venous sampling fails or is inappropriate. We present reference values for both venous and capillary samples of Protein S100B in children. Neurologically healthy children aged 1-16, scheduled for minor surgery requiring general anesthesia, were prospectively included. Samples for S100B were drawn before (venous) and after (venous and capillary) sedation. Serum values of 455 children (255 boys, 200 girls) aged 1-14 were computed. S100B was higher in younger children for both venous (r=-0.32) and capillary samples (r=-0.28). Reference levels for children aged 1 and 2 were significantly higher than for children aged 3-14 years (venous 0.15 μg/L, capillary 0.37 μg/L). For capillary blood, a gender difference was found in the youngest age groups. We present reference values for venous and capillary S100B in healthy children. These results can be utilized when considering future studies on pediatric head injury and S100B levels. Copyright © 2011 Elsevier B.V. All rights reserved.
Matthias L. Schroeter - One of the best experts on this subject based on the ideXlab platform.
-
Glial pathology is modified by age in mood disorders--a systematic meta-analysis of serum S100B in vivo studies.
Journal of affective disorders, 2010Co-Authors: Matthias L. Schroeter, Johann Steiner, Karsten MuellerAbstract:Mood disorders are characterized by specific glial pathology. Recently, based on histopathological post mortem studies, the glial hypothesis has been discussed as a dynamic process, in particular with regard to glioplasticity. Whereas in young subjects with mood disorders, glial cell density or glial cell numbers are reduced, they are increased in elderly subjects. To validate this concept in vivo, we investigated the dynamic course of glial pathology in mood disorders across studies measuring the glial marker Protein S100B in serum in a systematic and quantitative meta-analysis according to the QUOROM and PRISMA statement. We searched for studies in PubMed and Medline, applied strict inclusion/exclusion criteria, and calculated effect sizes according to Cohen and Hedges. The final meta-analysis included 174 subjects with mood disorders and 102 control subjects. It demonstrated higher levels of the glial marker Protein S100B in older compared with younger adult subjects suffering from mood disorders, although both young and older subjects showed elevated values in comparison to control subjects. Illness duration and age at onset had no impact on serum S100B. Influences of antidepressive drugs vs. the spontaneous course of the illness, differences between mood disorder subtypes and the specific role of S100B have to be investigated in future longitudinal studies. The meta-analysis indicates a modifying effect of S100B in mood disorders in the interaction with age, with an increasing role across the lifespan. Results are relevant for the understanding of mood disorders and future illness modifying therapies because S100B may influence neuro- and glioplasticity. Copyright © 2010 Elsevier B.V. All rights reserved.
-
Glial pathology is modified by age in mood disorders — A systematic meta-analysis of serum S100B in vivo studies
Journal of Affective Disorders, 2010Co-Authors: Matthias L. Schroeter, Johann Steiner, Karsten MuellerAbstract:Abstract Background Mood disorders are characterized by specific glial pathology. Recently, based on histopathological post mortem studies, the glial hypothesis has been discussed as a dynamic process, in particular with regard to glioplasticity. Whereas in young subjects with mood disorders, glial cell density or glial cell numbers are reduced, they are increased in elderly subjects. Methods To validate this concept in vivo, we investigated the dynamic course of glial pathology in mood disorders across studies measuring the glial marker Protein S100B in serum in a systematic and quantitative meta-analysis according to the QUOROM and PRISMA statement. We searched for studies in PubMed and Medline, applied strict inclusion/exclusion criteria, and calculated effect sizes according to Cohen and Hedges. Results The final meta-analysis included 174 subjects with mood disorders and 102 control subjects. It demonstrated higher levels of the glial marker Protein S100B in older compared with younger adult subjects suffering from mood disorders, although both young and older subjects showed elevated values in comparison to control subjects. Illness duration and age at onset had no impact on serum S100B. Limitations Influences of antidepressive drugs vs. the spontaneous course of the illness, differences between mood disorder subtypes and the specific role of S100B have to be investigated in future longitudinal studies. Conclusions The meta-analysis indicates a modifying effect of S100B in mood disorders in the interaction with age, with an increasing role across the lifespan. Results are relevant for the understanding of mood disorders and future illness modifying therapies because S100B may influence neuro- and glioplasticity.
-
Elevated serum levels of the glial marker Protein S100B are not specific for schizophrenia or mood disorders
Molecular psychiatry, 2009Co-Authors: Matthias L. Schroeter, Johann SteinerAbstract:Elevated serum levels of the glial marker Protein S100B are not specific for schizophrenia or mood disorders
Karsten Mueller - One of the best experts on this subject based on the ideXlab platform.
-
Glial pathology is modified by age in mood disorders--a systematic meta-analysis of serum S100B in vivo studies.
Journal of affective disorders, 2010Co-Authors: Matthias L. Schroeter, Johann Steiner, Karsten MuellerAbstract:Mood disorders are characterized by specific glial pathology. Recently, based on histopathological post mortem studies, the glial hypothesis has been discussed as a dynamic process, in particular with regard to glioplasticity. Whereas in young subjects with mood disorders, glial cell density or glial cell numbers are reduced, they are increased in elderly subjects. To validate this concept in vivo, we investigated the dynamic course of glial pathology in mood disorders across studies measuring the glial marker Protein S100B in serum in a systematic and quantitative meta-analysis according to the QUOROM and PRISMA statement. We searched for studies in PubMed and Medline, applied strict inclusion/exclusion criteria, and calculated effect sizes according to Cohen and Hedges. The final meta-analysis included 174 subjects with mood disorders and 102 control subjects. It demonstrated higher levels of the glial marker Protein S100B in older compared with younger adult subjects suffering from mood disorders, although both young and older subjects showed elevated values in comparison to control subjects. Illness duration and age at onset had no impact on serum S100B. Influences of antidepressive drugs vs. the spontaneous course of the illness, differences between mood disorder subtypes and the specific role of S100B have to be investigated in future longitudinal studies. The meta-analysis indicates a modifying effect of S100B in mood disorders in the interaction with age, with an increasing role across the lifespan. Results are relevant for the understanding of mood disorders and future illness modifying therapies because S100B may influence neuro- and glioplasticity. Copyright © 2010 Elsevier B.V. All rights reserved.
-
Glial pathology is modified by age in mood disorders — A systematic meta-analysis of serum S100B in vivo studies
Journal of Affective Disorders, 2010Co-Authors: Matthias L. Schroeter, Johann Steiner, Karsten MuellerAbstract:Abstract Background Mood disorders are characterized by specific glial pathology. Recently, based on histopathological post mortem studies, the glial hypothesis has been discussed as a dynamic process, in particular with regard to glioplasticity. Whereas in young subjects with mood disorders, glial cell density or glial cell numbers are reduced, they are increased in elderly subjects. Methods To validate this concept in vivo, we investigated the dynamic course of glial pathology in mood disorders across studies measuring the glial marker Protein S100B in serum in a systematic and quantitative meta-analysis according to the QUOROM and PRISMA statement. We searched for studies in PubMed and Medline, applied strict inclusion/exclusion criteria, and calculated effect sizes according to Cohen and Hedges. Results The final meta-analysis included 174 subjects with mood disorders and 102 control subjects. It demonstrated higher levels of the glial marker Protein S100B in older compared with younger adult subjects suffering from mood disorders, although both young and older subjects showed elevated values in comparison to control subjects. Illness duration and age at onset had no impact on serum S100B. Limitations Influences of antidepressive drugs vs. the spontaneous course of the illness, differences between mood disorder subtypes and the specific role of S100B have to be investigated in future longitudinal studies. Conclusions The meta-analysis indicates a modifying effect of S100B in mood disorders in the interaction with age, with an increasing role across the lifespan. Results are relevant for the understanding of mood disorders and future illness modifying therapies because S100B may influence neuro- and glioplasticity.
